DE3856326D1 - 2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen - Google Patents

2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen

Info

Publication number: DE3856326D1
Authority: DE; Germany
Prior art keywords: compound; thioadenylyl; water; antiviral; antiviral uses
Prior art date: 1987-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE3856326T

Other languages

English (en)

Other versions

DE3856326T2 (de

Inventor

Robert J Suhadolnik

Wolfgang Pfleiderer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Temple University of Commonwealth System of Higher Education

Original Assignee

Temple University of Commonwealth System of Higher Education

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-22

Filing date

1988-10-18

Publication date

1999-05-20

1988-10-18 Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education

1999-05-20 Publication of DE3856326D1 publication Critical patent/DE3856326D1/de

1999-12-02 Application granted granted Critical

1999-12-02 Publication of DE3856326T2 publication Critical patent/DE3856326T2/de

2008-10-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

DE3856326T 1987-10-22 1988-10-18 2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen Expired - Fee Related DE3856326T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/112,591 US4924624A (en)	1987-10-22	1987-10-22	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof

Publications (2)

Publication Number	Publication Date
DE3856326D1 true DE3856326D1 (de)	1999-05-20
DE3856326T2 DE3856326T2 (de)	1999-12-02

Family

ID=22344763

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE3855135T Expired - Fee Related DE3855135T2 (de)	1987-10-22	1988-10-18	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen
DE3856326T Expired - Fee Related DE3856326T2 (de)	1987-10-22	1988-10-18	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE3855135T Expired - Fee Related DE3855135T2 (de)	1987-10-22	1988-10-18	2',5'-phosphorothioat-oligoadenylate und deren antivirale verwendungen

Country Status (8)

Country	Link
US (3)	US4924624A (de)
EP (2)	EP0694559B1 (de)
JP (1)	JP2733777B2 (de)
AT (2)	ATE178902T1 (de)
AU (1)	AU2628088A (de)
CA (1)	CA1339953C (de)
DE (2)	DE3855135T2 (de)
WO (1)	WO1989003683A1 (de)

Families Citing this family (837)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643889A (en) *	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US5550111A (en) *	1984-07-11	1996-08-27	Temple University-Of The Commonwealth System Of Higher Education	Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
JP2976436B2 (ja) *	1988-04-27	1999-11-10	味の素株式会社	新規オリゴリボヌクレオチド誘導体及び抗ウイルス剤への使用
AU658562B2 (en)	1989-10-24	1995-04-27	Isis Pharmaceuticals, Inc.	2' modified oligonucleotides
US5635488A (en) *	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US5587361A (en) *	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5620963A (en) *	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5470967A (en) *	1990-04-10	1995-11-28	The Dupont Merck Pharmaceutical Company	Oligonucleotide analogs with sulfamate linkages
US6446032B1 (en) *	1990-09-21	2002-09-03	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove
US6041910A (en) *	1997-09-22	2000-03-28	Jervis B. Webb Company	Baggage pusher device and system
GB9111967D0 (en) *	1991-06-04	1991-07-24	Erba Carlo Spa	2,5'-nucleotide analogs as antiviral agents
US5571799A (en) *	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
WO1993003733A1 (en) *	1991-08-12	1993-03-04	Basco, Ltd.	Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues
US5607923A (en) *	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5654284A (en) *	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en) *	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5599797A (en) *	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en) *	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
NZ249715A (en) *	1992-03-12	1997-07-27	Univ Temple	2',5'-oligoadenylate derivatives; compounds, pharmaceutical compositions and conjugates
US6537973B1 (en)	1992-03-16	2003-03-25	Isis Pharmaceuticals, Inc.	Oligonucleotide inhibition of protein kinase C
US20040127446A1 (en) *	1992-05-14	2004-07-01	Lawrence Blatt	Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5532130A (en) *	1993-07-20	1996-07-02	Dyad Pharmaceutical Corporation	Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
EP0728139B1 (de)	1993-09-03	2003-08-13	Isis Pharmaceuticals, Inc.	Aminoderivatisierte nukleoside und oligonukleoside
US6653458B1 (en)	1993-09-03	2003-11-25	Isis Pharmaceuticals, Inc.	Modified oligonucleotides
US7276335B1 (en) *	1993-09-29	2007-10-02	Massachusetts Institute Of Technology	Designing compounds specifically inhibiting ribonucleic acid function
NZ291713A (en) *	1994-09-14	1998-01-26	Univ Temple	2',5'-phosphorothioate/phosphodiester oligoadenylates
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
US5855911A (en) *	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5854033A (en)	1995-11-21	1998-12-29	Yale University	Rolling circle replication reporter systems
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171028A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US6111085A (en) *	1996-09-13	2000-08-29	Isis Pharmaceuticals, Inc.	Carbamate-derivatized nucleosides and oligonucleosides
US6977244B2 (en) *	1996-10-04	2005-12-20	Board Of Regents, The University Of Texas Systems	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6468991B1 (en)	1997-01-16	2002-10-22	Cyclis Pharmaceuticals, Inc.	Method of treating rhinoviral infections
US5955446A (en) *	1997-01-16	1999-09-21	Pentose Pharmaceuticals, Inc.	Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds
AU7804798A (en)	1997-06-12	1998-12-30	Temple University - Of The Commonwealth System Of Higher Education	Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof
US6362171B1 (en)	1997-06-12	2002-03-26	Temple University-Of The Commonwealth System Of Higher Education	Aminoaklanoyl-linked conjugates of 2′,5′-oligoadenylate and antiviral uses thereof
EP1012331B1 (de)	1997-07-01	2006-03-29	Isis Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
AU8512598A (en) *	1997-07-25	1999-02-16	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US7704962B1 (en)	1997-10-03	2010-04-27	Board Of Regents, The University Of Texas System	Small oligonucleotides with anti-tumor activity
US7285288B1 (en)	1997-10-03	2007-10-23	Board Of Regents, The University Of Texas System	Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
WO2000018885A1 (en)	1998-09-29	2000-04-06	Gamida Cell Ltd.	Methods of controlling proliferation and differentiation of stem and progenitor cells
US20040186071A1 (en) *	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
EP1080103A4 (de) *	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
AU753270B2 (en) *	1998-05-21	2002-10-10	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6461815B1 (en) *	1998-05-22	2002-10-08	North Carolina State University	Antibacterial agents and methods of screening for the same
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US7534605B2 (en) *	1999-06-08	2009-05-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
DE19940748A1 (de) *	1999-08-27	2001-03-01	Hugo Seinfeld	Arzneimittel enthaltend xenogene Oligo- oder/und Polyribonukleotide
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
DE60140864D1 (de) *	2000-04-13	2010-02-04	Thomas N Wight	Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US6656700B2 (en)	2000-05-26	2003-12-02	Amersham Plc	Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) *	2000-05-26	2004-02-03	Amersham Plc	Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US20060166227A1 (en) *	2000-06-20	2006-07-27	Stephen Kingsmore	Protein expression profiling
US6323009B1 (en) *	2000-06-28	2001-11-27	Molecular Staging, Inc.	Multiply-primed amplification of nucleic acid sequences
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020123474A1 (en) *	2000-10-04	2002-09-05	Shannon Mark E.	Human GTP-Rho binding protein2
EP2336166A1 (de)	2000-10-12	2011-06-22	University Of Rochester	Zusammensetzungen die die Proliferation von Krebszellen hemmen
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
KR20020069627A (ko) *	2001-02-27	2002-09-05	동부한농화학 주식회사	육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
ES2328796T3 (es)	2001-03-14	2009-11-18	Myriad Genetics, Inc.	Interaccion tsg101-gag y uso de la misma.
CA2633171C (en)	2001-06-20	2012-11-20	Genentech, Inc.	Antibodies against tumor-associated antigenic target (tat) polypeptides
AU2002315393A1 (en)	2001-06-21	2003-01-08	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
DE10133858A1 (de)	2001-07-12	2003-02-06	Aventis Pharma Gmbh	Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US6822088B2 (en)	2001-07-17	2004-11-23	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides on solid support
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US20030109476A1 (en) *	2001-08-07	2003-06-12	Kmiec Eric B.	Compositions and methods for the prevention and treatment of Huntington's disease
US20040096880A1 (en) *	2001-08-07	2004-05-20	Kmiec Eric B.	Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
DE60238143D1 (de)	2001-09-18	2010-12-09	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ577565A (en)	2001-10-09	2010-10-29	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
WO2003057160A2 (en)	2002-01-02	2003-07-17	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
IL152904A0 (en)	2002-01-24	2003-06-24	Gamida Cell Ltd	Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) *	2002-01-25	2003-07-31	Gamida-Cell Ltd.	Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7553619B2 (en) *	2002-02-08	2009-06-30	Qiagen Gmbh	Detection method using dissociated rolling circle amplification
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
MXPA04010092A (es)	2002-04-16	2004-12-13	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20030199464A1 (en)	2002-04-23	2003-10-23	Silviu Itescu	Regeneration of endogenous myocardial tissue by induction of neovascularization
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
WO2003106617A2 (en) *	2002-06-12	2003-12-24	Tel Aviv Medical Center Research Development Fund	Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
AU2003276131A1 (en) *	2002-06-18	2003-12-31	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
US20050287648A1 (en)	2002-08-05	2005-12-29	University Of Rochester	Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
CN1694959B (zh)	2002-09-13	2013-09-18	雷普利瑟公司	非序列互补的抗病毒寡核苷酸
EP1546170A4 (de) *	2002-09-20	2007-08-29	Univ Yale	Riboswitche, verfahren zu deren anwendung und zusammensetzungen, die mit riboswitchen verwendet werden
EP1549767A4 (de)	2002-09-26	2006-06-07	Amgen Inc	Modulation der expression von forkhead-box o1a
WO2004110345A2 (en) *	2002-10-29	2004-12-23	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9827263B2 (en)	2002-11-05	2017-11-28	Ionis Pharmaceuticals, Inc.	2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504929C (en)	2002-11-05	2014-07-22	Charles Allerson	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2336318B1 (de)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense-modulation von apolipoprotein-b-expression
ES2420914T3 (es)	2002-11-13	2013-08-27	Genzyme Corporation	Modulación antisentido de la expresión de la apolipoproteína B
US20060009378A1 (en)	2002-11-14	2006-01-12	Itshak Golan	Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
JP4915980B2 (ja)	2002-11-15	2012-04-11	エムユーエスシーファウンデーションフォーリサーチデベロップメント	補体レセプター２標的化補体調節因子
US7754450B2 (en) *	2002-11-15	2010-07-13	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
EP1624753B1 (de)	2002-11-21	2012-01-25	The University of Utah Research Foundation	Purinerge geruchsmodulation
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US9487823B2 (en)	2002-12-20	2016-11-08	Qiagen Gmbh	Nucleic acid amplification
WO2004058987A2 (en)	2002-12-20	2004-07-15	Qiagen Gmbh	Nucleic acid amplification
US6977153B2 (en) *	2002-12-31	2005-12-20	Qiagen Gmbh	Rolling circle amplification of RNA
ES2400033T3 (es)	2003-02-11	2013-04-05	Antisense Therapeutics Ltd	Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en)	2003-03-31	2011-10-25	Qiagen Gmbh	Universal reagents for rolling circle amplification and methods of use
US20040198640A1 (en) *	2003-04-02	2004-10-07	Dharmacon, Inc.	Stabilized polynucleotides for use in RNA interference
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
WO2004093788A2 (en) *	2003-04-17	2004-11-04	The Trustees Of Columbia University In The City Ofnew York	Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
EP1633770B1 (de)	2003-06-13	2015-04-29	Alnylam Europe AG	Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
WO2005027962A1 (en) *	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
US7425544B2 (en)	2003-09-18	2008-09-16	Eli Lilly And Company	Modulation of eIF4E expression
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
EP1689432B1 (de)	2003-11-17	2009-12-30	Genentech, Inc.	Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
JP2007513134A (ja) *	2003-12-05	2007-05-24	ビオヴィトルム・アクチボラゲット	２−置換アデノシンの改善された合成
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US8778900B2 (en) *	2004-01-22	2014-07-15	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP1 expression
US7468431B2 (en)	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US7842459B2 (en)	2004-01-27	2010-11-30	Compugen Ltd.	Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
EP1713900A4 (de) *	2004-01-27	2009-06-17	Compugen Ltd	Verfahren und systeme zur kommentierung biomolekularer sequenzen
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en)	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
KR101147147B1 (ko)	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050267300A1 (en)	2004-04-05	2005-12-01	Muthiah Manoharan	Processes and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
AU2005323437B2 (en)	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
EP3225633B1 (de)	2004-05-21	2020-03-25	The UAB Research Foundation	Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
CA2569036A1 (en) *	2004-06-03	2005-12-22	Balkrishen Bhat	Chimeric gapped oligomeric compositions
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
CA2569419A1 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006030442A2 (en) *	2004-09-16	2006-03-23	Gamida-Cell Ltd.	Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
WO2006032144A1 (en) *	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
WO2006050999A2 (en) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S	Methods of reducing body fat
US20060166234A1 (en)	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
CN101175769A (zh)	2005-03-10	2008-05-07	健泰科生物技术公司	用于调控血管完整性的方法和组合物
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US8309303B2 (en) *	2005-04-01	2012-11-13	Qiagen Gmbh	Reverse transcription and amplification of RNA with simultaneous degradation of DNA
EP1891141B1 (de)	2005-05-31	2016-11-16	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
US20090209621A1 (en)	2005-06-03	2009-08-20	The Johns Hopkins University	Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
CA2614531C (en)	2005-07-07	2015-06-16	Avraham Hochberg	Nucleic acid agents for downregulating h19, and methods of using same
US7776532B2 (en)	2005-08-11	2010-08-17	Synthetic Genomics, Inc.	Method for in vitro recombination
JP2009504168A (ja)	2005-08-17	2009-02-05	メディクシスエス．エー．	Ｃｋ１９発現を確認する組成物及び方法
WO2007027775A2 (en)	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP1762627A1 (de)	2005-09-09	2007-03-14	Qiagen GmbH	Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
IL172297A (en)	2005-10-03	2016-03-31	Compugen Ltd	Soluble vegfr-1 variants for the diagnosis of preeclampsia
EP2392645A1 (de)	2005-10-14	2011-12-07	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
JP5111385B2 (ja)	2005-10-28	2013-01-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン遺伝子の発現を抑制するための組成物および方法
AU2006311730B2 (en)	2005-11-09	2010-12-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
JP2009516710A (ja)	2005-11-21	2009-04-23	アイシスファーマシューティカルズ，インコーポレーテッド	ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
US8846393B2 (en)	2005-11-29	2014-09-30	Gamida-Cell Ltd.	Methods of improving stem cell homing and engraftment
JP2009524411A (ja) *	2005-12-21	2009-07-02	イェールユニバーシティー	リボスイッチの調節に関連した方法および組成物
JP5713377B2 (ja)	2005-12-28	2015-05-07	ザスクリプスリサーチインスティテュート	薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US20100184021A1 (en)	2006-01-16	2010-07-22	Compugen Ltd.	Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
EP2388328A1 (de)	2006-01-27	2011-11-23	Isis Pharmaceuticals, Inc.	Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
ES2516815T3 (es)	2006-01-27	2014-10-31	Isis Pharmaceuticals, Inc.	Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
EP2527354A1 (de)	2006-03-31	2012-11-28	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5-Gens
US8586554B2 (en)	2006-05-05	2013-11-19	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of PTP1B
DE102006020885A1 (de) *	2006-05-05	2007-11-08	Qiagen Gmbh	Einführung von Sequenzelementen in Nukleinsäuren
EP3872179A1 (de)	2006-05-11	2021-09-01	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
DK2066684T3 (da) *	2006-05-11	2012-10-22	Isis Pharmaceuticals Inc	5´-Modificerede bicycliske nukleinsyreanaloge
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2652770A1 (en)	2006-05-19	2007-11-29	Alnylam Pharmaceuticals, Inc.	Rnai modulation of aha and therapeutic uses thereof
WO2007137220A2 (en)	2006-05-22	2007-11-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
US9506056B2 (en)	2006-06-08	2016-11-29	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
US20100137440A1 (en) *	2006-09-11	2010-06-03	Yale University	Lysine riboswitches, structure-based compound design with lysine riboswitches, and methods and compositions for use of and with lysine riboswitches
AU2007299629C1 (en)	2006-09-21	2012-05-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the HAMP gene
CA2663601C (en)	2006-09-22	2014-11-25	Dharmacon, Inc.	Duplex oligonucleotide complexes and methods for gene silencing by rna interference
KR101129509B1 (ko)	2006-10-03	2012-04-13	알닐람 파마슈티칼스 인코포레이티드	지질 함유 조성물
EP2081596A4 (de)	2006-10-06	2010-07-21	Univ Utah Res Found	Verfahren zum nachweis von augenkrankheiten und pathologischen zuständen und behandlung dafür
US8999317B2 (en)	2006-11-01	2015-04-07	University Of Rochester	Methods and compositions related to the structure and function of APOBEC3G
KR20090089462A (ko)	2006-12-11	2009-08-21	유니버시티 오브 유타 리써치 파운데이션	병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
US20100129358A1 (en)	2006-12-22	2010-05-27	University Of Utah Research Foundation	Method of detecting ocular diseases and pathologic conditions and treatment of same
ATE548454T1 (de) *	2007-01-16	2012-03-15	Yissum Res Dev Co	Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
US20100196403A1 (en) *	2007-01-29	2010-08-05	Jacob Hochman	Antibody conjugates for circumventing multi-drug resistance
KR101488800B1 (ko)	2007-02-09	2015-02-04	노오쓰웨스턴 유니버시티	세포내 타겟 검출용 입자
CN101801185A (zh)	2007-03-22	2010-08-11	耶鲁大学	与控制可变剪接的核糖开关有关的方法和组合物
PE20090064A1 (es)	2007-03-26	2009-03-02	Novartis Ag	Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
AU2008232891B2 (en)	2007-03-29	2012-01-12	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the Ebola
US20110091377A1 (en)	2007-05-11	2011-04-21	The Johns Hopkins University	Biomarkers for melanoma
CA2687684A1 (en) *	2007-05-29	2008-12-11	Yale University	Methods and compositions related to riboswitches that control alternative splicing and rna processing
SG174103A1 (en) *	2007-05-29	2011-09-29	Univ Yale	Riboswitches and methods and compositions for use of and with riboswitches
AU2008260277C1 (en)	2007-05-30	2014-04-17	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
EP2176280B2 (de) *	2007-07-05	2015-06-24	Isis Pharmaceuticals, Inc.	6-disubstituierte bizyklische nukleinsäureanaloga
CN103215269B (zh)	2007-07-05	2015-01-21	诺瓦提斯公司	用于治疗病毒感染的dsRNA
US8088904B2 (en)	2007-08-15	2012-01-03	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
JP2010537638A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
JP2010538005A (ja)	2007-08-28	2010-12-09	ユーエービーリサーチファウンデーション	合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
PL2769729T3 (pl)	2007-09-04	2019-09-30	Compugen Ltd.	Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
WO2009039466A1 (en)	2007-09-20	2009-03-26	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) *	2007-09-21	2009-03-26	California Institute Of Technology	Nfia in glial fate determination, glioma therapy and astrocytoma treatment
EP2205741A2 (de)	2007-10-02	2010-07-14	Amgen Inc.	ERHÖHUNG DES ERYTHROPOIETINSPIEGELS MITTELS VERWENDUNG VON MIT miRNA HYBRIDISIERBAREN NUKLEINSÄUREN UND VORLÄUFER DAVON
JP2011502502A (ja) *	2007-11-05	2011-01-27	バルティックテクロノジーデヴェロプメント，リミテッド	核酸のハイブリッド形成における修飾塩基を含むオリゴヌクレオチドの使用
US8097712B2 (en)	2007-11-07	2012-01-17	Beelogics Inc.	Compositions for conferring tolerance to viral disease in social insects, and the use thereof
EP2222851B1 (de) *	2007-11-20	2017-06-28	Ionis Pharmaceuticals, Inc.	Modulation der cd40-expression
WO2009067647A1 (en) *	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Carbocyclic alpha-l-bicyclic nucleic acid analogs
JP5530933B2 (ja)	2007-12-10	2014-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	第ｖｉｉ因子遺伝子発現阻害のための組成物及び方法
WO2009086558A1 (en)	2008-01-02	2009-07-09	Tekmira Pharmaceuticals Corporation	Improved compositions and methods for the delivery of nucleic acids
US8530640B2 (en) *	2008-02-07	2013-09-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
CA2715289C (en) *	2008-02-11	2019-12-24	Rxi Pharmaceuticals Corporation	Modified rnai polynucleotides and uses thereof
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
EA019531B1 (ru)	2008-03-05	2014-04-30	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ Eg5 И VEGF
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009124238A1 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
JP5685182B2 (ja)	2008-04-18	2015-03-18	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	初発自己免疫性糖尿病を予防するため、および／または逆転させるためのマイクロスフェアに基づく組成物
EP2280995A2 (de) *	2008-04-29	2011-02-09	Wyeth LLC	Verfahren zur behandlung von entzündungen
US8082730B2 (en) *	2008-05-20	2011-12-27	Caterpillar Inc.	Engine system having particulate reduction device and method
CA2728467A1 (en) *	2008-07-15	2010-01-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of tgf-beta receptor genes
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
US20110237646A1 (en) *	2008-08-07	2011-09-29	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
AU2009275387B2 (en)	2008-08-25	2010-07-08	Excaliard Pharmaceuticals, Inc.	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2331690B1 (de)	2008-09-02	2016-01-13	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und verfahren zur hemmung der expression eines mutierten egfr-gens
CN108165548B (zh)	2008-09-22	2022-10-14	菲奥医药公司	减小大小的自递送RNAi化合物
WO2010036696A1 (en)	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
US8501805B2 (en) *	2008-09-24	2013-08-06	Isis Pharmaceuticals, Inc.	Substituted alpha-L-bicyclic nucleosides
EP2334793B1 (de)	2008-09-25	2016-04-06	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
EP2743265B1 (de)	2008-10-09	2017-03-15	Arbutus Biopharma Corporation	Verbesserte Aminolipide und Verfahren zur Freisetzung von Nukleinsäuren
PL2379084T3 (pl)	2008-10-15	2018-04-30	Ionis Pharmaceuticals, Inc.	Modulowanie ekspresji czynnika XI
IL302142B1 (en)	2008-10-20	2024-03-01	Alnylam Pharmaceuticals Inc	Compounds and methods for inhibiting transthyretin expression
US20120059045A1 (en)	2008-10-24	2012-03-08	Isis Pharmaceuticals, Inc.	Methods of using oligomeric compounds comprising 2'-substituted nucleosides
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
MX2011004909A (es) *	2008-11-17	2011-05-30	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes del factor vii.
US9074211B2 (en)	2008-11-19	2015-07-07	Rxi Pharmaceuticals Corporation	Inhibition of MAP4K4 through RNAI
DK2365803T3 (en)	2008-11-24	2018-01-22	Univ Northwestern	POLYVALENT RNA NANOPARTICLE COMPOSITIONS
WO2010061393A1 (en)	2008-11-30	2010-06-03	Compugen Ltd.	He4 variant nucleotide and amino acid sequences, and methods of use thereof
EP2370580B1 (de)	2008-12-04	2019-09-11	CuRNA, Inc.	Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
CN102317458B (zh)	2008-12-04	2018-01-02	库尔纳公司	通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
WO2010065787A2 (en)	2008-12-04	2010-06-10	Curna, Inc.	Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
EP2633854B1 (de)	2008-12-05	2015-09-16	Yeda Research And Development Co. Ltd.	miRNA-9 or miRNA-9* zur Verwendung in der Behandlung von ALS
AU2009324534B2 (en)	2008-12-10	2015-07-30	Alnylam Pharmaceuticals, Inc.	GNAQ targeted dsRNA compositions and methods for inhibiting expression
WO2010080554A1 (en)	2008-12-17	2010-07-15	Avi Biopharma, Inc.	Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AU2010203474B2 (en) *	2009-01-08	2015-11-19	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
US20100233270A1 (en)	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101546673B1 (ko) *	2009-01-15	2015-08-25	삼성전자주식회사	전자 사진용 토너 및 그의 제조방법
WO2010088537A2 (en)	2009-01-29	2010-08-05	Alnylam Pharmaceuticals, Inc.	Improved lipid formulation
AU2010211133A1 (en)	2009-02-03	2011-07-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of PTP1B genes
WO2010090762A1 (en)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
CA2752239C (en)	2009-02-12	2021-03-30	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
JP5766126B2 (ja)	2009-02-12	2015-08-19	クルナ・インコーポレーテッド	脳由来神経栄養因子（ｂｄｎｆ）関連疾病の、ｂｄｎｆに対する天然アンチセンス転写物の抑制による治療
US20120041051A1 (en)	2009-02-26	2012-02-16	Kevin Fitzgerald	Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
WO2010101951A1 (en)	2009-03-02	2010-09-10	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
EP2403946A4 (de)	2009-03-04	2012-11-14		Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
US20100267806A1 (en)	2009-03-12	2010-10-21	David Bumcrot	LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CN102482677B (zh)	2009-03-16	2017-10-17	库尔纳公司	通过抑制nrf2的天然反义转录物治疗核因子(红细胞衍生2)‑样2(nrf2)相关疾病
CN102549159B (zh)	2009-03-17	2016-08-10	库尔纳公司	通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
CA2757694C (en)	2009-04-15	2020-10-06	Northwestern University	Delivery of oligonucleotide-functionalized nanoparticles
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
DK2424987T3 (en)	2009-05-01	2018-02-26	Curna Inc	TREATMENT OF HEMOGLOBIN (HBF / HBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO HBF / HBG
AU2010245933B2 (en)	2009-05-05	2016-06-16	Arbutus Biopharma Corporation	Methods of delivering oligonucleotides to immune cells
NZ596186A (en)	2009-05-05	2014-03-28	Alnylam Pharmaceuticals Inc	Lipid compositions
ES2609655T3 (es)	2009-05-06	2017-04-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
WO2010129799A2 (en)	2009-05-06	2010-11-11	Curna, Inc.	Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010132665A1 (en)	2009-05-15	2010-11-18	Yale University	Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
BRPI1012769A2 (pt) *	2009-05-15	2018-01-30	Hoffmann La Roche	composições e métodos para inibir expressão de genes de receptor de glicocorticóide (gcr)
EP2432881B1 (de)	2009-05-18	2017-11-15	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
WO2010135695A2 (en)	2009-05-22	2010-11-25	Curna, Inc.	TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
US20100303795A1 (en) *	2009-05-27	2010-12-02	Soerensen Karina Dalsgaard	Marker of prostate cancer
ES2618576T3 (es)	2009-05-28	2017-06-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
HUE038796T2 (hu)	2009-06-10	2018-11-28	Arbutus Biopharma Corp	Továbbfejlesztett lipid készítmény
WO2010148050A2 (en)	2009-06-16	2010-12-23	Curna, Inc.	Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (ja)	2009-06-16	2017-05-17	クルナ・インコーポレーテッド	パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
WO2011005595A2 (en) *	2009-06-24	2011-01-13	Alios Biopharma, Inc.	2-5a analogs and their methods of use
WO2010151671A2 (en)	2009-06-24	2010-12-29	Curna, Inc.	Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en)	2009-06-26	2010-12-29	Opko Curna, Llc	Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US9512164B2 (en)	2009-07-07	2016-12-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
US8927513B2 (en)	2009-07-07	2015-01-06	Alnylam Pharmaceuticals, Inc.	5′ phosphate mimics
CA2769665A1 (en)	2009-08-05	2011-02-10	Opko Curna, Llc	Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (de)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclische cyclohexosenukleinsäureanaloga
EP2464336A4 (de)	2009-08-14	2013-11-20	Alnylam Pharmaceuticals Inc	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
WO2011022420A1 (en)	2009-08-17	2011-02-24	Yale University	Methylation biomarkers and methods of use
KR101892760B1 (ko)	2009-08-25	2018-08-28	큐알엔에이, 인크.	ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
AU2010289400B2 (en)	2009-09-02	2014-10-23	Curis, Inc.	Mutant smoothened and methods of using the same
WO2011044902A1 (en)	2009-10-13	2011-04-21	Aarhus Universitet	Tff3 hypomethylation as a novel biomarker for prostate cancer
CN105368836A (zh)	2009-10-14	2016-03-02	耶路撒冷希伯来大学伊森姆研究发展公司	用于控制蜂中的瓦螨的组合物
US8962584B2 (en)	2009-10-14	2015-02-24	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Compositions for controlling Varroa mites in bees
CA2778442A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
JP6147502B2 (ja)	2009-10-27	2017-06-14	スウィフトバイオサイエンシーズ，インコーポレイテッド	ポリヌクレオチドプライマー及びプローブ
US9376690B2 (en)	2009-10-30	2016-06-28	Northwestern University	Templated nanoconjugates
KR20120102674A (ko)	2009-11-03	2012-09-18	유니버시티 오브 버지니아 페이턴트 파운데이션	중합체 분석물을 검출하는 다용도의 가시적인 방법
AR078921A1 (es) *	2009-11-09	2011-12-14	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
WO2011058555A1 (en)	2009-11-12	2011-05-19	Yeda Research And Development Co. Ltd.	A method of editing dna in a cell and constructs capable of same
CN102712928B (zh)	2009-11-13	2017-08-04	萨雷普塔治疗公司	反义抗病毒化合物及治疗流感病毒感染的方法
CA2781469A1 (en)	2009-11-23	2011-05-26	Swift Biosciences, Inc.	Devices to extend single stranded target molecules
CN102741294A (zh)	2009-11-30	2012-10-17	霍夫曼-拉罗奇有限公司	治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
NO2513310T3 (de)	2009-12-16	2018-03-31
US9068183B2 (en)	2009-12-23	2015-06-30	Curna, Inc.	Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
CN102869776B (zh)	2009-12-23	2017-06-23	库尔纳公司	通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
CA2785173A1 (en)	2009-12-29	2011-07-28	Curna, Inc.	Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853508B1 (ko)	2009-12-29	2018-06-20	큐알엔에이, 인크.	종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
US8946181B2 (en)	2010-01-04	2015-02-03	Curna, Inc.	Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (ru)	2010-01-06	2017-03-02	Курна, Инк.	Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011085347A2 (en)	2010-01-11	2011-07-14	Opko Curna, Llc	Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011088076A2 (en)	2010-01-12	2011-07-21	Yale University	Structured rna motifs and compounds and methods for their use
CN102782135A (zh)	2010-01-25	2012-11-14	库尔纳公司	通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
CA2824843A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
WO2011095174A1 (en)	2010-02-08	2011-08-11	Aarhus Universitet	Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum
CA2790506A1 (en)	2010-02-22	2011-08-25	Curna, Inc.	Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
PE20130214A1 (es)	2010-02-23	2013-03-11	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011107100A1 (en)	2010-03-03	2011-09-09	Aarhus Universitet	Methods and compositions for regulation of herv4
MY163887A (en)	2010-03-08	2017-11-15	Monsanto Technology Llc	Polynucleotide molecules for gene regulations in plants
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2545173A2 (de)	2010-03-12	2013-01-16	Sarepta Therapeutics, Inc.	Antisense-modulation von nukleären hormonrezeptoren
ES2743600T3 (es)	2010-03-12	2020-02-20	Brigham & Womens Hospital Inc	Métodos de tratamiento de los trastornos inflamatorios vasculares
WO2011113054A2 (en)	2010-03-12	2011-09-15	Aurasense Llc	Crosslinked polynucleotide structure
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2550001B1 (de)	2010-03-24	2019-05-22	Phio Pharmaceuticals Corp.	Rna-interferenz bei augenerkrankungen
WO2011119852A1 (en)	2010-03-24	2011-09-29	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
KR20180044433A (ko)	2010-03-24	2018-05-02	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2011120046A2 (en)	2010-03-26	2011-09-29	Swift Biosciences, Inc.	Methods and compositions for isolating polynucleotides
AU2011235276B2 (en)	2010-03-29	2015-09-03	Alnylam Pharmaceuticals, Inc.	SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
TWI644675B (zh)	2010-04-09	2018-12-21	可娜公司	藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病
US20110269194A1 (en)	2010-04-20	2011-11-03	Swift Biosciences, Inc.	Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
EP3173419A1 (de)	2010-04-28	2017-05-31	Ionis Pharmaceuticals, Inc.	Modifizierte nukleoside, analoga davon und daraus hergestellte oligomere verbindungen
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
MX343559B (es)	2010-04-29	2016-11-10	Ionis Pharmaceuticals Inc	Modulacion de la expresion de transtiretina.
CN107988228B (zh)	2010-05-03	2022-01-25	库尔纳公司	通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
MX342239B (es)	2010-05-03	2016-09-21	Genentech Inc *	Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2569431B1 (de)	2010-05-13	2015-09-23	Sarepta Therapeutics, Inc.	Methoden zur identifizierung von verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
US20130203045A1 (en)	2010-05-26	2013-08-08	University Of Virginia Patent Foundation	Method for detecting nucleic acids based on aggregate formation
DK2576783T3 (en)	2010-05-26	2018-03-12	Curna Inc	TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
EP2576579B1 (de)	2010-06-02	2018-08-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von leberfibrose
WO2011156278A1 (en)	2010-06-07	2011-12-15	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en)	2010-06-08	2011-12-15	Isis Pharmaceuticals, Inc.	Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en)	2010-06-11	2017-05-02	Vanderbilt University	Multiplexed interferometric detection system and method
WO2011163466A1 (en)	2010-06-23	2011-12-29	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CA2805024A1 (en)	2010-06-30	2012-01-05	Compugen Ltd.	Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders
NO2593547T3 (de)	2010-07-14	2018-04-14
US20130143955A1 (en)	2010-08-09	2013-06-06	Yale University	Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
US20130210901A1 (en)	2010-09-20	2013-08-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Method of treating neurodegenerative diseases
WO2012047968A2 (en)	2010-10-05	2012-04-12	Genentech, Inc.	Mutant smoothened and methods of using the same
RU2624048C2 (ru)	2010-10-06	2017-06-30	Курна, Инк.	Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
CN103517990A (zh)	2010-10-07	2014-01-15	通用医疗公司	癌症生物标志物
US8951983B2 (en)	2010-10-17	2015-02-10	Yeda Research And Development Co. Ltd.	Methods and compositions for the treatment of insulin-associated medical conditions
EP3434772A3 (de)	2010-10-18	2019-03-20	Arrowhead Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
KR101913232B1 (ko)	2010-10-27	2018-10-30	큐알엔에이, 인크.	인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
CN110123830A (zh)	2010-11-09	2019-08-16	阿尔尼拉姆医药品有限公司	用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
GB201019043D0 (en)	2010-11-10	2010-12-22	Protea Biopharma N V	Use of 2',5'-oligoadenylate derivative compounds
DK2638163T3 (en)	2010-11-12	2017-07-24	Massachusetts Gen Hospital	POLYCOMB-ASSOCIATED NON-CODING RNAs
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
JP6071893B2 (ja)	2010-11-23	2017-02-01	カッパーアールエヌエー，インコーポレイテッド	Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
US9150926B2 (en)	2010-12-06	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
US9127275B2 (en)	2010-12-10	2015-09-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
EP2670404B1 (de)	2011-02-02	2018-08-29	The Trustees of Princeton University	Sirtuin-modulatoren als modulatoren der virusproduktion
MX365647B (es)	2011-02-02	2019-06-10	Excaliard Pharmaceuticals Inc	El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
KR102365961B1 (ko)	2011-03-29	2022-02-23	알닐람 파마슈티칼스 인코포레이티드	Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2694660B1 (de)	2011-04-03	2018-08-08	The General Hospital Corporation	Effiziente in-vivo-proteinexpression mittels modifizierter rna (mod-rna)
WO2012140627A1 (en)	2011-04-15	2012-10-18	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012149154A1 (en)	2011-04-26	2012-11-01	Swift Biosciences, Inc.	Polynucleotide primers and probes
WO2012151268A1 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en)	2011-05-02	2012-11-08	University Of Virginia Patent Foundation	Method and system to detect aggregate formation on a substrate
CN103620036B (zh)	2011-06-09	2016-12-21	库尔纳公司	通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2723351B1 (de)	2011-06-21	2018-02-14	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
AU2012272970A1 (en)	2011-06-21	2014-02-06	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
CA3191066A1 (en)	2011-06-21	2012-12-27	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
EP2723390B1 (de)	2011-06-23	2017-12-27	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
CN103635576B (zh)	2011-06-30	2016-09-21	箭头研究公司	用于抑制乙型肝炎病毒的基因表达的组合物和方法
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
CA2844012C (en)	2011-08-04	2021-03-16	Yeda Research And Development Co. Ltd.	Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US10806146B2 (en)	2011-09-13	2020-10-20	Monsanto Technology Llc	Methods and compositions for weed control
BR112014005958A2 (pt)	2011-09-13	2020-10-13	Monsanto Technology Llc	métodos e composições químicas agrícolas para controle de planta, método de redução de expressão de um gene accase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene accase e composição herbicida
UY34328A (es)	2011-09-13	2013-04-30	Monsanto Technology Llc	?composiciones y métodos para controlar malezas comprendiendo un polinucleótido y agente de transferencia, y que modulan protoporfirinógeno ix oxidasa?.
US9840715B1 (en)	2011-09-13	2017-12-12	Monsanto Technology Llc	Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10829828B2 (en)	2011-09-13	2020-11-10	Monsanto Technology Llc	Methods and compositions for weed control
WO2013040057A1 (en)	2011-09-13	2013-03-21	Monsanto Technology Llc	Methods and compositions for weed control
CA2848685A1 (en)	2011-09-13	2013-03-21	Monsanto Technology Llc	Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide
US10760086B2 (en)	2011-09-13	2020-09-01	Monsanto Technology Llc	Methods and compositions for weed control
WO2013040499A1 (en)	2011-09-14	2013-03-21	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
US9920326B1 (en)	2011-09-14	2018-03-20	Monsanto Technology Llc	Methods and compositions for increasing invertase activity in plants
DK2756080T3 (da)	2011-09-14	2019-05-20	Translate Bio Ma Inc	Multimeriske oligonukleotidforbindelser
US9580713B2 (en)	2011-09-17	2017-02-28	Yale University	Fluoride-responsive riboswitches, fluoride transporters, and methods of use
EP2766482B1 (de)	2011-10-11	2016-12-07	The Brigham and Women's Hospital, Inc.	Mikro-rnas in neurodegenerativen erkrankungen
RS57645B1 (sr)	2011-10-14	2018-11-30	Hoffmann La Roche	Anti-htra1 antitela i načini primene
FR2981650B1 (fr) *	2011-10-24	2013-12-27	Univ Paris Curie	Analogues de nucleosides pour le traitement d'une infection virale et methode d'evaluation de la sensibilite audit traitement
EP2771464B1 (de)	2011-10-27	2018-03-21	Yeda Research and Development Co. Ltd.	Verfahren zur behandlung von karzinomen
WO2013090457A2 (en)	2011-12-12	2013-06-20	Oncoimmunin Inc.	In vivo delivery of oligonucleotides
SG2014008304A (en)	2012-02-01	2014-06-27	Compugen Ltd	C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013121426A1 (en)	2012-02-13	2013-08-22	Gamida-Cell Ltd.	Culturing of mesenchymal stem cells
EP3401393B1 (de)	2012-02-22	2020-02-19	Exostem Biotec Ltd	Mikrornas zur erzeugung von astrocyten
WO2013124816A2 (en)	2012-02-22	2013-08-29	Brainstem Biotec Ltd.	Generation of neural stem cells and motor neurons
JP6509723B2 (ja)	2012-03-13	2019-05-08	スウィフトバイオサイエンシーズ，インコーポレイテッド	核酸ポリメラーゼによる基質ポリヌクレオチドの大きさ制御されたホモポリマーテーリングのための方法および組成物
ES2694592T3 (es)	2012-03-15	2018-12-21	Curna, Inc.	Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
US9610362B2 (en)	2012-03-16	2017-04-04	Valerion Therapeutics, Llc	Antisense conjugates for decreasing expression of DMPK
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9221864B2 (en)	2012-04-09	2015-12-29	Isis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
CN107083385A (zh)	2012-04-20	2017-08-22	艾珀特玛治疗公司	产热的miRNA调节剂
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
US20150152410A1 (en)	2012-05-16	2015-06-04	Rana Therapeutics, Inc.	Compositions and methods for modulating mecp2 expression
US10059941B2 (en)	2012-05-16	2018-08-28	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
CA2873809A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
MX360866B (es)	2012-05-24	2018-11-09	A B Seeds Ltd	Composiciones y métodos para silenciar la expresión genética.
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
US20140038182A1 (en)	2012-07-17	2014-02-06	Dna Logix, Inc.	Cooperative primers, probes, and applications thereof
US9175266B2 (en)	2012-07-23	2015-11-03	Gamida Cell Ltd.	Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en)	2012-07-23	2017-02-14	Gamida Cell Ltd.	Methods of culturing and expanding mesenchymal stem cells
WO2014022852A1 (en)	2012-08-03	2014-02-06	Aptamir Therapeutics, Inc.	Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9403865B2 (en)	2012-08-15	2016-08-02	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
AU2013306006B2 (en)	2012-08-20	2017-07-06	The Regents Of The University Of California	Polynucleotides having bioreversible groups
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US10077451B2 (en)	2012-10-18	2018-09-18	Monsanto Technology Llc	Methods and compositions for plant pest control
AU2013337277B2 (en)	2012-11-05	2018-03-08	Foundation Medicine, Inc.	Novel NTRK1 fusion molecules and uses thereof
WO2014106838A2 (en)	2013-01-01	2014-07-10	A.B. Seeds Ltd.	Methods of introducing dsrna to plant seeds for modulating gene expression
US10683505B2 (en)	2013-01-01	2020-06-16	Monsanto Technology Llc	Methods of introducing dsRNA to plant seeds for modulating gene expression
EP3939614A1 (de)	2013-01-18	2022-01-19	Foundation Medicine, Inc.	Verfahren zur behandlung cholangiokarzinom
US10000767B2 (en)	2013-01-28	2018-06-19	Monsanto Technology Llc	Methods and compositions for plant pest control
WO2014120861A2 (en)	2013-01-31	2014-08-07	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
DK2958998T3 (en) *	2013-02-22	2018-04-16	Sirna Therapeutics Inc	SHORT INTERFERATING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2'-INTERNUCLEOSIDE BOND
US20150366890A1 (en)	2013-02-25	2015-12-24	Trustees Of Boston University	Compositions and methods for treating fungal infections
US10612019B2 (en)	2013-03-13	2020-04-07	Monsanto Technology Llc	Methods and compositions for weed control
AU2014249015B2 (en)	2013-03-13	2020-04-16	Monsanto Technology Llc	Methods and compositions for weed control
US20140283211A1 (en)	2013-03-14	2014-09-18	Monsanto Technology Llc	Methods and Compositions for Plant Pest Control
PT2970974T (pt)	2013-03-14	2017-11-29	Alnylam Pharmaceuticals Inc	Composições de irna de componente do complemento c5 e métodos para a sua utilização
US10568328B2 (en)	2013-03-15	2020-02-25	Monsanto Technology Llc	Methods and compositions for weed control
EP4286517A3 (de)	2013-04-04	2024-03-13	President and Fellows of Harvard College	Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen
RU2686080C2 (ru)	2013-05-01	2019-04-24	Ионис Фармасьютикалз, Инк.	Композиции и способы
SG10201804472YA (en)	2013-05-22	2018-07-30	Alnylam Pharmaceuticals Inc	SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SG11201510565TA (en)	2013-05-22	2016-01-28	Alnylam Pharmaceuticals Inc	Tmprss6 irna compositions and methods of use thereof
EP3004396B1 (de)	2013-06-06	2019-10-16	The General Hospital Corporation	Zusammensetzungen zur krebsbehandlung
ES2862125T3 (es)	2013-06-13	2021-10-07	Antisense Therapeutics Ltd	Terapia combinada para acromegalia
BR112016000555B1 (pt)	2013-07-19	2022-12-27	Monsanto Technology Llc	Método para controlar uma infestação da espécie de leptinotarsa em uma planta, composição inseticida e construção de dna recombinante
US9850496B2 (en)	2013-07-19	2017-12-26	Monsanto Technology Llc	Compositions and methods for controlling Leptinotarsa
CN105579582A (zh)	2013-07-25	2016-05-11	埃克西奎雷股份有限公司	用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
HUE048710T2 (hu)	2013-08-08	2020-08-28	Scripps Research Inst	Eljárás nukleinsavak in vitro helyspecifikus enzimes jelölésére nem-természetes nukleotidok beépítésével
EP3868772A1 (de)	2013-09-30	2021-08-25	Geron Corporation	Phosphorodiamidat-rückgratverbindung für oligonukleotide
US10077444B2 (en)	2013-10-02	2018-09-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
US10519446B2 (en)	2013-10-04	2019-12-31	Novartis Ag	Organic compounds to treat hepatitis B virus
KR102298475B1 (ko)	2013-10-04	2021-09-06	노파르티스 아게	ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
LT3052628T (lt)	2013-10-04	2020-09-10	Alnylam Pharmaceuticals, Inc.	Kompozicijos ir būdai alas1 geno raiškai nuslopinti
EP3055426B1 (de)	2013-10-09	2019-06-19	The United States of America as represented by The Secretary Department of Health and Human Services	Nachweis von hepatitis delta virus (hdv) zur diagnose und behandlung von sjögren-syndrom und lymphom
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
EP3060680B1 (de)	2013-10-21	2019-02-27	The General Hospital Corporation	Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und krebsbehandlung
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
WO2015066708A1 (en)	2013-11-04	2015-05-07	Northwestern University	Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
CA2929533C (en)	2013-11-04	2023-06-06	Monsanto Technology Llc	Compositions and methods for controlling arthropod parasite and pest infestations
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
US10182988B2 (en)	2013-12-03	2019-01-22	Northwestern University	Liposomal particles, methods of making same and uses thereof
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
US10385388B2 (en)	2013-12-06	2019-08-20	Swift Biosciences, Inc.	Cleavable competitor polynucleotides
UA119253C2 (uk)	2013-12-10	2019-05-27	Біолоджикс, Інк.	Спосіб боротьби із вірусом у кліща varroa та у бджіл
EP3798306A1 (de)	2013-12-12	2021-03-31	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-irna-zusammensetzungen und verfahren zur verwendung davon
US10900083B2 (en)	2013-12-20	2021-01-26	The General Hospital Corporation	Methods and assays relating to circulating tumor cells
MX368629B (es)	2014-01-15	2019-10-08	Monsanto Technology Llc	Metodos y composiciones para el control de malezas utilizando polinucleotidos de 5-enolpiruvilshikimato-3-fosfato sintasa (epsps).
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
WO2015118537A2 (en)	2014-02-05	2015-08-13	Yeda Research And Development Co. Ltd.	Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
KR20230152154A (ko)	2014-02-11	2023-11-02	알닐람 파마슈티칼스 인코포레이티드	케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
SG11201607761UA (en)	2014-03-19	2016-10-28	Ionis Pharmaceuticals Inc	Compositions for modulating ataxin 2 expression
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
PT3757214T (pt)	2014-04-01	2022-08-26	Biogen Ma Inc	Composições para modulação da expressão de sod-1
BR112016022711A2 (pt)	2014-04-01	2017-10-31	Monsanto Technology Llc	composições e métodos para controle de pragas de inseto
EP3943607A1 (de)	2014-04-09	2022-01-26	The Scripps Research Institute	Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3137119B1 (de)	2014-04-28	2020-07-01	Phio Pharmaceuticals Corp.	Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
PE20170010A1 (es)	2014-05-01	2017-03-04	Ionis Pharmaceuticals Inc	Composiciones y metodos para modular la expresion del factor b del complemento
EP3137115B1 (de)	2014-05-01	2020-10-14	Ionis Pharmaceuticals, Inc.	Verfahren zur synthese von reaktiven konjugatclustern
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
SG10202104570TA (en)	2014-05-22	2021-06-29	Alnylam Pharmaceuticals Inc	Angiotensinogen (agt) irna compositions and methods of use thereof
AU2015270925A1 (en)	2014-06-02	2016-12-22	Children's Medical Center Corporation	Methods and compositions for immunomodulation
EP3155100B1 (de)	2014-06-10	2021-12-22	Erasmus University Medical Center Rotterdam	Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide
CA2953347A1 (en)	2014-06-23	2015-12-30	Monsanto Technology Llc	Compositions and methods for regulating gene expression via rna interference
EP3161138A4 (de)	2014-06-25	2017-12-06	Monsanto Technology LLC	Verfahren und zusammensetzungen zur zuführung von nukleinsäuren an pflanzenzellen und regulierung der genexpression
WO2015200697A1 (en)	2014-06-25	2015-12-30	The General Hospital Corporation	Targeting human satellite ii (hsatii)
ES2799404T3 (es)	2014-07-15	2020-12-17	Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd	Polipéptidos de CD44 aislados y usos de los mismos
US9951327B1 (en)	2014-07-17	2018-04-24	Integrated Dna Technologies, Inc.	Efficient and rapid method for assembling and cloning double-stranded DNA fragments
RU2021123470A (ru)	2014-07-29	2021-09-06	Монсанто Текнолоджи Ллс	Композиции и способы борьбы с насекомыми-вредителями
JP7081923B2 (ja)	2014-07-31	2022-06-07	ユーエイビーリサーチファンデーション	アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
CA2958431A1 (en)	2014-08-19	2016-02-25	Northwestern University	Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016030899A1 (en)	2014-08-28	2016-03-03	Yeda Research And Development Co. Ltd.	Methods of treating amyotrophic lateral scleroses
ES2928500T3 (es)	2014-08-29	2022-11-18	Alnylam Pharmaceuticals Inc	Patisirán para su uso en el tratamiento de amiloidosis mediada por transtiretina
EP4043567A1 (de)	2014-08-29	2022-08-17	Children's Medical Center Corporation	Verfahren und zusammensetzungen zur krebsbehandlung
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3188799B1 (de)	2014-09-05	2022-07-06	Phio Pharmaceuticals Corp.	Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
EP3663403A1 (de)	2014-09-26	2020-06-10	University of Massachusetts	Rna-modulierende stoffe
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3904519A1 (de)	2014-10-30	2021-11-03	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016081444A1 (en)	2014-11-17	2016-05-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CA2968531A1 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
JP6997623B2 (ja)	2014-12-12	2022-02-04	エム．ウルフ、トッド	オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016115490A1 (en)	2015-01-16	2016-07-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of dux4
PL3256589T3 (pl)	2015-01-22	2022-02-21	Monsanto Technology Llc	Kompozycje i sposoby kontrolowania leptinotarsa
WO2016118812A1 (en)	2015-01-23	2016-07-28	Vanderbilt University	A robust interferometer and methods of using same
EP3256487A4 (de)	2015-02-09	2018-07-18	Duke University	Zusammensetzungen und verfahren zur epigenombearbeitung
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016137923A1 (en)	2015-02-23	2016-09-01	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
EP3262173A2 (de)	2015-02-23	2018-01-03	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von humangenetischen erkrankungen einschliesslich hämoglobinopathien
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
EP3268475B1 (de)	2015-03-11	2020-10-21	Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd.	Köderoligonukleotide zur behandlung von krankheiten
EP4218771A1 (de)	2015-03-27	2023-08-02	Yeda Research and Development Co. Ltd	Verfahren zur behandlung von motoneuronenerkrankungen
KR20180020125A (ko)	2015-03-27	2018-02-27	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	변형된 t 세포 및 이의 제조 및 사용 방법
US10961532B2 (en)	2015-04-07	2021-03-30	The General Hospital Corporation	Methods for reactivating genes on the inactive X chromosome
US10745702B2 (en)	2015-04-08	2020-08-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
MX2017014215A (es)	2015-05-04	2018-03-28	Monsanto Technology Llc	Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos.
US20180161300A1 (en)	2015-05-11	2018-06-14	Yeda Research And Development Co., Ltd.	Citrin inhibitors for the treatment of cancer
CN107750125A (zh)	2015-06-02	2018-03-02	孟山都技术有限公司	用于将多核苷酸递送至植物中的组合物和方法
WO2016196782A1 (en)	2015-06-03	2016-12-08	Monsanto Technology Llc	Methods and compositions for introducing nucleic acids into plants
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
JP2018524588A (ja)	2015-06-26	2018-08-30	ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド	骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
CA2991045A1 (en)	2015-06-29	2017-01-05	Caris Science, Inc.	Therapeutic oligonucleotides binding c1q
WO2017007813A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en)	2015-07-06	2017-01-12	Rxi Pharmaceuticals Corporation	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
WO2017021963A1 (en)	2015-08-03	2017-02-09	Biokine Therapeutics Ltd.	Cxcr4 binding agents for treatment of diseases
WO2017021961A1 (en)	2015-08-04	2017-02-09	Yeda Research And Development Co. Ltd.	Methods of screening for riboswitches and attenuators
US10130651B2 (en)	2015-08-07	2018-11-20	Arrowhead Pharmaceuticals, Inc.	RNAi Therapy for Hepatitis B Virus Infection
SG10202007937SA (en)	2015-09-02	2020-09-29	Alnylam Pharmaceuticals Inc	PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20190048340A1 (en)	2015-09-24	2019-02-14	Crispr Therapeutics Ag	Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
WO2017070151A1 (en)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
US20180311176A1 (en)	2015-10-26	2018-11-01	Translate Bio Ma, Inc.	Nanoparticle formulations for delivery of nucleic acid complexes
US11369692B2 (en)	2015-10-28	2022-06-28	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of Duchenne Muscular Dystrophy
PE20181009A1 (es)	2015-10-30	2018-06-26	Genentech Inc	ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
ES2938883T3 (es)	2015-11-05	2023-04-17	Los Angeles Childrens Hospital	Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
BR112018008971A2 (pt)	2015-11-06	2018-11-27	Crispr Therapeutics Ag	materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
WO2017081686A1 (en)	2015-11-10	2017-05-18	B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University	Means and methods for reducing tumorigenicity of cancer stem cells
US11001622B2 (en)	2015-11-19	2021-05-11	The Brigham And Women's Hospital, Inc.	Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
EP3967758A1 (de)	2015-12-01	2022-03-16	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
US10993995B2 (en)	2015-12-07	2021-05-04	Erasmus University Medical Center Rotterdam	Enzymatic replacement therapy and antisense therapy for pompe disease
US11761007B2 (en)	2015-12-18	2023-09-19	The Scripps Research Institute	Production of unnatural nucleotides using a CRISPR/Cas9 system
EP3394260B1 (de)	2015-12-23	2021-02-17	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyothrophischer lateraler sklerose und/oder frontotemporaler demenz
US10907160B2 (en)	2016-01-05	2021-02-02	Ionis Pharmaceuticals, Inc.	Methods for reducing LRRK2 expression
US10627396B2 (en)	2016-01-29	2020-04-21	Vanderbilt University	Free-solution response function interferometry
US20190038771A1 (en)	2016-02-02	2019-02-07	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017136558A1 (en)	2016-02-04	2017-08-10	Curis, Inc.	Mutant smoothened and methods of using the same
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
CA3054284A1 (en)	2016-02-25	2017-08-31	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting smoc2
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
WO2017161172A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Methods of modulating keap1
WO2017158422A1 (en)	2016-03-16	2017-09-21	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
CA3018066A1 (en)	2016-03-18	2017-09-21	Caris Science, Inc.	Oligonucleotide probes and uses thereof
CA3021467A1 (en)	2016-04-18	2017-10-26	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
AU2017271579B2 (en)	2016-05-25	2023-10-19	Caris Science, Inc.	Oligonucleotide probes and uses thereof
US20190256845A1 (en)	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
EP3471781A4 (de)	2016-06-17	2020-05-06	Ionis Pharmaceuticals, Inc.	Modulierung der gys1-expression
HUE060123T2 (hu)	2016-06-24	2023-01-28	Scripps Research Inst	Új nukleozid-trifoszfát-transzporter és alkalmazásai
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
US11564997B2 (en)	2016-06-29	2023-01-31	Crispr Therapeutics Ag	Materials and methods for treatment of friedreich ataxia and other related disorders
EP3478313B1 (de)	2016-06-29	2022-05-04	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
CN109843914B (zh)	2016-07-06	2024-03-15	沃泰克斯药物股份有限公司	用于治疗疼痛相关病症的材料和方法
US11801313B2 (en)	2016-07-06	2023-10-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
CA3030701A1 (en)	2016-07-11	2018-01-18	Translate Bio Ma, Inc.	Nucleic acid conjugates and uses thereof
CN109844103A (zh)	2016-07-21	2019-06-04	美克斯细胞有限公司	用于修饰基因组dna的方法和组合物
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
JOP20170161A1 (ar)	2016-08-04	2019-01-30	Arrowhead Pharmaceuticals Inc	عوامل RNAi للعدوى بفيروس التهاب الكبد ب
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
HUE059718T2 (hu)	2016-09-02	2022-12-28	Dicerna Pharmaceuticals Inc	4'-foszfát analógok és azokat tartalmazó oligonukleotidok
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
CN109661233A (zh)	2016-10-06	2019-04-19	Ionis 制药公司	缀合低聚化合物的方法
US11459568B2 (en)	2016-10-31	2022-10-04	University Of Massachusetts	Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
EP3548620A4 (de)	2016-12-02	2020-07-22	Cold Spring Harbor Laboratory	Modulation der lnc05-expression
US11753460B2 (en)	2016-12-13	2023-09-12	Seattle Children's Hospital	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
AU2017376950B2 (en)	2016-12-16	2024-02-22	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
SG11201905508VA (en)	2017-01-23	2019-08-27	Regeneron Pharma	Hsd17b13 variants and uses thereof
WO2018154462A2 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
JP2020508056A (ja)	2017-02-22	2020-03-19	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	遺伝子編集のための組成物および方法
WO2018154418A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154459A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
US11559588B2 (en)	2017-02-22	2023-01-24	Crispr Therapeutics Ag	Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
WO2018165564A1 (en)	2017-03-09	2018-09-13	Ionis Pharmaceuticals, Inc.	Morpholino modified oligomeric compounds
WO2018183969A1 (en)	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform for efficient analysis of candidate molecules and methods of making and using the platform
TWI801377B (zh)	2017-04-18	2023-05-11	美商阿尼拉製藥公司	治療具有ｂ型肝炎病毒（ｈｂｖ）感染之個體之方法
WO2018193428A1 (en)	2017-04-20	2018-10-25	Synthena Ag	Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
JP2020517613A (ja)	2017-04-20	2020-06-18	シンセナアーゲー	トリシクロｄｎａヌクレオシドを含む改変オリゴマー化合物およびその使用
US11767520B2 (en)	2017-04-20	2023-09-26	Atyr Pharma, Inc.	Compositions and methods for treating lung inflammation
WO2018195486A1 (en)	2017-04-21	2018-10-25	The Broad Institute, Inc.	Targeted delivery to beta cells
KR20200005596A (ko)	2017-05-12	2020-01-15	크리스퍼 테라퓨틱스 아게	세포를 엔지니어링하기 위한 물질 및 방법, 및 면역-종양학에서의 그의 용도
AU2018300069A1 (en)	2017-07-11	2020-02-27	Synthorx, Inc.	Incorporation of unnatural nucleotides and methods thereof
JP7277432B2 (ja)	2017-07-13	2023-05-19	アルナイラムファーマシューティカルズ，インコーポレイテッド	乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
KR20200028997A (ko)	2017-07-13	2020-03-17	노오쓰웨스턴 유니버시티	올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
US20200181220A1 (en)	2017-08-03	2020-06-11	Synthorx, Inc.	Cytokine conjugates for the treatment of proliferative and infectious diseases
US11197884B2 (en)	2017-08-18	2021-12-14	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019051173A1 (en)	2017-09-08	2019-03-14	Ionis Pharmaceuticals, Inc.	MODULATORS OF SMAD7 EXPRESSION
KR20200089656A (ko)	2017-09-19	2020-07-27	알닐람 파마슈티칼스 인코포레이티드	트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
CA3079172A1 (en)	2017-10-17	2019-04-25	Crispr Therapeutics Ag	Compositions and methods for gene editing for hemophilia a
US20210180091A1 (en)	2017-10-26	2021-06-17	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
AU2018360697A1 (en)	2017-11-01	2020-05-14	Alnylam Pharmaceuticals, Inc.	Complement component C3 iRNA compositions and methods of use thereof
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
WO2019092505A1 (en)	2017-11-09	2019-05-16	Casebia Therapeutics Llp	Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof
US20200385719A1 (en)	2017-11-16	2020-12-10	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (de)	2017-11-20	2020-09-30	Alnylam Pharmaceuticals, Inc.	Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
US20190153440A1 (en)	2017-11-21	2019-05-23	Casebia Therapeutics Llp	Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CA3084955A1 (en)	2017-12-05	2019-06-13	Vertex Pharmaceuticals Incorporated	Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
EP3724332A1 (de)	2017-12-14	2020-10-21	CRISPR Therapeutics AG	Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und anderen anwendungen
BR112020012088A2 (pt)	2017-12-18	2020-11-17	Alnylam Pharmaceuticals, Inc.	composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
JP7402163B2 (ja)	2017-12-21	2023-12-20	クリスパーセラピューティクスアーゲー	２ａ型アッシャー症候群の処置のための材料および方法
WO2019126641A2 (en)	2017-12-21	2019-06-27	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
CA3084633A1 (en)	2017-12-21	2019-06-27	Crispr Therapeutics Ag	Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CA3088180A1 (en)	2018-01-12	2019-07-18	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting transferrin
MX2020007369A (es)	2018-01-15	2020-10-28	Ionis Pharmaceuticals Inc	Moduladores de la expresion de dnm2.
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
EP3749768A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
US11566236B2 (en)	2018-02-05	2023-01-31	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of hemoglobinopathies
EP3749368A1 (de)	2018-02-08	2020-12-16	Yeda Research and Development Co. Ltd	Verfahren zur identifizierung und verwendung von mitteln zur behandlung von mit darmbarrierefunktionsstörungen einhergehenden krankheiten
US20210130824A1 (en)	2018-02-16	2021-05-06	Crispr Therapeutics Ag	Compositions and methods for gene editing by targeting fibrinogen-alpha
CA3091857A1 (en)	2018-02-26	2019-08-29	Synthorx, Inc.	Il-15 conjugates and uses thereof
US11732260B2 (en)	2018-03-02	2023-08-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for the modulation of amyloid-β precursor protein
TW202000199A (zh)	2018-03-02	2020-01-01	美商Ionis製藥公司	Irf4 表現之調節劑
CN112105625A (zh)	2018-03-07	2020-12-18	赛诺菲	核苷酸前体、核苷酸类似物以及含其的寡聚化合物
WO2019183150A1 (en)	2018-03-19	2019-09-26	Casebia Therapeutics Limited Liability Partnership	Novel rna-programmable endonuclease systems and uses thereof
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
EP4051799A2 (de)	2018-03-30	2022-09-07	Rheinische Friedrich-Wilhelms-Universität Bonn	Aptamere zur gezielten aktivierung von t-zellvermittelter immunität
AU2019247490A1 (en)	2018-04-06	2020-10-22	Children's Medical Center Corporation	Compositions and methods for somatic cell reprogramming and modulating imprinting
EP3775204A4 (de)	2018-04-11	2021-12-29	Ionis Pharmaceuticals, Inc.	Modulatoren der ezh2-expression
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
UY38225A (es)	2018-05-09	2019-11-29	Ionis Pharmaceuticals Inc	Compuestos y métodos para reducir de la expresión de atxn3
MX2020011913A (es)	2018-05-09	2021-01-29	Ionis Pharmaceuticals Inc	Compuestos y metodos para la reduccion de la expresion de fxi.
TW202016304A (zh)	2018-05-14	2020-05-01	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
WO2019241648A1 (en)	2018-06-14	2019-12-19	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing stmn2 expression
US11332746B1 (en)	2018-06-27	2022-05-17	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing LRRK2 expression
JP2021529518A (ja)	2018-06-28	2021-11-04	クリスパーセラピューティクスアーゲー	ドナーポリヌクレオチドの挿入によるゲノム編集のための組成物および方法
JOP20210018A1 (ar)	2018-07-25	2021-01-21	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير الوراثي عن atxn2
EA202190528A1 (ru)	2018-08-13	2021-04-23	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20210348162A1 (en)	2018-08-16	2021-11-11	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
US20210292766A1 (en)	2018-08-29	2021-09-23	University Of Massachusetts	Inhibition of Protein Kinases to Treat Friedreich Ataxia
US20220056220A1 (en)	2018-09-14	2022-02-24	Northwestern University	Programming protein polymerization with dna
WO2020060986A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
US20210348159A1 (en)	2018-10-17	2021-11-11	Crispr Therapeutics Ag	Compositions and methods for delivering transgenes
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
EP3880821A4 (de)	2018-11-15	2023-01-25	Ionis Pharmaceuticals, Inc.	Modulatoren der irf5-expression
IL263184A (en)	2018-11-21	2020-05-31	Yarden Yosef	Method of treating cancer and compositions for same
WO2020118259A1 (en)	2018-12-06	2020-06-11	Northwestern University	Protein crystal engineering through dna hybridization interactions
HRP20231338T1 (hr)	2018-12-20	2024-02-16	Vir Biotechnology, Inc.	Kombinirana terapija hbv
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
MX2021008628A (es)	2019-01-16	2021-11-17	Genzyme Corp	Composiciones de arni para serpinc1 y metodos de uso de las mismas.
JP2022519532A (ja)	2019-01-31	2022-03-24	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｙａｐ１発現のモジュレーター
MX2021009259A (es)	2019-02-06	2021-08-24	Synthorx Inc	Conjugados de il-2 y metodos de uso del mismo.
SG11202108357PA (en)	2019-02-15	2021-08-30	Crispr Therapeutics Ag	Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
EP3927378A1 (de)	2019-02-21	2021-12-29	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Verfahren zur reduktion von arzneimittelinduzierter nephrotoxizität
MX2021010152A (es)	2019-02-27	2021-09-14	Ionis Pharmaceuticals Inc	Moduladores de la expresion de malat1.
MA55297A (fr)	2019-03-12	2022-01-19	Bayer Healthcare Llc	Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
JP2022527108A (ja)	2019-03-29	2022-05-30	ディセルナファーマシューティカルズインコーポレイテッド	Ｋｒａｓ関連疾患または障害の治療のための組成物及び方法
JP2022527105A (ja)	2019-03-29	2022-05-30	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｕｂｅ３ａ－ａｔｓを調節するための化合物及び方法
CA3136676A1 (en)	2019-05-03	2020-11-12	Dicerna Pharmaceuticals, Inc.	Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20210047649A1 (en)	2019-05-08	2021-02-18	Vertex Pharmaceuticals Incorporated	Crispr/cas all-in-two vector systems for treatment of dmd
US20220339256A1 (en)	2019-05-13	2022-10-27	Vir Biotechnology, Inc.	Compositions and methods for treating hepatitis b virus (hbv) infection
JP2022538784A (ja)	2019-06-14	2022-09-06	ザスクリプスリサーチインスティテュート	半合成生物における複製、転写および翻訳のための試薬ならびに方法
US20210008161A1 (en)	2019-06-17	2021-01-14	Crispr Therapeutics Ag	Methods and compositions for improved homology directed repair
EP3956450A4 (de)	2019-07-26	2022-11-16	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation von gfap
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (de)	2019-08-13	2022-06-22	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
WO2021030778A1 (en)	2019-08-15	2021-02-18	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
WO2021030706A1 (en)	2019-08-15	2021-02-18	Synthorx, Inc.	Immuno oncology combination therapies with il-2 conjugates
CA3148135A1 (en)	2019-08-23	2021-03-04	Carolina E. CAFFARO	Il-15 conjugates and uses thereof
MX2022002689A (es)	2019-09-03	2022-04-07	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de quimiotaxina derivada de celulas de leucocitos 2 (lect2).
KR20220061158A (ko)	2019-09-10	2022-05-12	신톡스, 인크.	자가면역질환을 치료하기 위한 il-2 접합체 및 사용 방법
EP4038189A1 (de)	2019-10-04	2022-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
EP4045652A1 (de)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
EP4048793A1 (de)	2019-10-22	2022-08-31	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
US20230040920A1 (en)	2019-11-01	2023-02-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
AR120341A1 (es)	2019-11-01	2022-02-09	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
MX2022005251A (es)	2019-11-04	2022-06-08	Synthorx Inc	Conjugados de interleuquina 10 y sus usos.
CN114981431A (zh)	2019-11-13	2022-08-30	阿尔尼拉姆医药品有限公司	用于治疗血管紧张素原(agt)相关病症的方法和组合物
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
CN115335521A (zh)	2019-11-27	2022-11-11	克里斯珀医疗股份公司	合成rna分子的方法
AU2020391116A1 (en) *	2019-11-27	2022-07-14	Alnylam Pharmaceuticals, Inc.	Synthesis of 3'-RNA oligonucleotides
EP4073251A1 (de)	2019-12-13	2022-10-19	Alnylam Pharmaceuticals, Inc.	Irna-wirkstoffzusammensetzungen des open reading frame 72 (c9orf72) des menschlichen chromosoms 9 und verfahren zu ihrer verwendung
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4077674A1 (de)	2019-12-18	2022-10-26	Alia Therapeutics S.R.L.	Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
US20230123981A1 (en)	2020-01-15	2023-04-20	Dicerna Pharmaceuticals, Inc.	4'-o-methylene phosphonate nucleic acids and analogues thereof
US20230057461A1 (en)	2020-01-27	2023-02-23	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CA3170377A1 (en)	2020-02-10	2021-08-19	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing vegf-a expression
CN115397989A (zh)	2020-02-18	2022-11-25	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
TW202140787A (zh)	2020-02-28	2021-11-01	美商Ionis製藥公司	用於調節ｓｍｎ２之化合物及方法
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178736A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
CN116209759A (zh)	2020-03-26	2023-06-02	阿尔尼拉姆医药品有限公司	冠状病毒iRNA组合物及其使用方法
WO2021202443A2 (en)	2020-03-30	2021-10-07	Alnylam Pharmaceucticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
BR112022020145A2 (pt)	2020-04-06	2023-01-03	Alnylam Pharmaceuticals Inc	Composições e métodos para silenciamento da expressão de myoc
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4133077A1 (de)	2020-04-07	2023-02-15	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
WO2021207189A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
KR20230018377A (ko)	2020-04-27	2023-02-07	알닐람 파마슈티칼스 인코포레이티드	아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
KR20230017789A (ko)	2020-04-30	2023-02-06	알닐람 파마슈티칼스 인코포레이티드	보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
WO2021222768A2 (en)	2020-05-01	2021-11-04	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating atxn1
EP4150078A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150076A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
EP4150077A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
EP4150089A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
CA3162416C (en)	2020-05-15	2023-07-04	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4153746A1 (de)	2020-05-21	2023-03-29	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
CA3179051A1 (en)	2020-05-22	2021-11-25	Chandra Vargeese	Double stranded oligonucleotide compositions and methods relating thereto
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4161552A1 (de)	2020-06-05	2023-04-12	The Broad Institute, Inc.	Zusammensetzungen und verfahren zur behandlung von neoplasien
EP4162050A1 (de)	2020-06-09	2023-04-12	Alnylam Pharmaceuticals, Inc.	Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
CN116209760A (zh)	2020-06-18	2023-06-02	阿尔尼拉姆医药品有限公司	黄嘌呤脱氢酶(XDH)iRNA组合物及其使用方法
BR112022026316A2 (pt)	2020-06-24	2023-03-07	Vir Biotechnology Inc	Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
TW202216203A (zh)	2020-06-25	2022-05-01	美商欣爍克斯公司	Il-2接合物及抗egfr抗體之免疫腫瘤學組合治療
CA3185749A1 (en)	2020-06-29	2022-01-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating plp1
IL300283A (en)	2020-08-04	2023-04-01	Dicerna Pharmaceuticals Inc	Systemic administration of oligonucleotides
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
US20220290136A1 (en)	2020-09-30	2022-09-15	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
EP3978608A1 (de)	2020-10-05	2022-04-06	SQY Therapeutics	Oligomere verbindung zur dystrophinrettung in dmd-patienten während des skipping exon-51
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
MX2023004032A (es)	2020-10-09	2023-04-27	Synthorx Inc	Terapias inmuno-oncologicas con conjugados de il-2.
MX2023004029A (es)	2020-10-09	2023-04-27	Synthorx Inc	Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
EP4228637A1 (de)	2020-10-15	2023-08-23	Yeda Research and Development Co. Ltd	Verfahren zur behandlung von myeloidmalignitäten
EP4232581A1 (de)	2020-10-21	2023-08-30	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
JP2023549500A (ja)	2020-11-13	2023-11-27	アルナイラムファーマシューティカルズ，インコーポレイテッド	凝固第Ｖ因子（Ｆ５）ｉＲＮＡ組成物およびその使用方法
EP4136092A4 (de)	2020-11-18	2023-10-11	Ionis Pharmaceuticals, Inc.	Verbindungen und verfahren zur modulation der angiotensinogenexpression
CA3202708A1 (en)	2020-11-23	2022-05-27	Alpha Anomeric Sas	Nucleic acid duplexes
TW202237150A (zh)	2020-12-01	2022-10-01	美商艾拉倫製藥股份有限公司	用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
EP4259795A1 (de)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3206285A1 (en)	2020-12-23	2022-06-30	Flagship Pioneering, Inc.	Compositions of modified trems and uses thereof
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
WO2022174000A2 (en)	2021-02-12	2022-08-18	Alnylam Pharmaceuticals, Inc.	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
EP4291243A1 (de)	2021-02-12	2023-12-20	Synthorx, Inc.	Lungenkrebskombinationstherapie mit il-2-konjugaten und einem anti-pd-1-antikörper oder antigenbindendem fragment davon
JP2024509783A (ja)	2021-02-25	2024-03-05	アルナイラムファーマシューティカルズ，インコーポレイテッド	プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
WO2022182574A1 (en)	2021-02-26	2022-09-01	Alnylam Pharmaceuticals, Inc.	KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022187435A1 (en)	2021-03-04	2022-09-09	Alnylam Pharmaceuticals, Inc.	Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4304640A1 (de)	2021-03-12	2024-01-17	Northwestern University	Antivirale impfstoffe mit kugelförmigen nukleinsäuren
WO2022192519A1 (en)	2021-03-12	2022-09-15	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
CA3214499A1 (en)	2021-03-29	2022-10-06	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
EP4330392A1 (de)	2021-04-26	2024-03-06	Alnylam Pharmaceuticals, Inc.	Transmembranprotease, serin 6 (tmprss6)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022232343A1 (en)	2021-04-29	2022-11-03	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022235537A1 (en)	2021-05-03	2022-11-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022246023A1 (en)	2021-05-20	2022-11-24	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
TW202313679A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法
BR112023025224A2 (pt)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
WO2022260939A2 (en)	2021-06-08	2022-12-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
BR112023023768A2 (pt)	2021-06-11	2024-02-27	Bayer Ag	Sistemas de endonucleases programáveis por rna tipo v
CA3223192A1 (en)	2021-06-18	2022-12-22	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing ifnar1 expression
WO2023278410A1 (en)	2021-06-29	2023-01-05	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
AU2022303164A1 (en)	2021-06-30	2024-01-18	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
IL309905A (en)	2021-07-23	2024-03-01	Alnylam Pharmaceuticals Inc	IRNA compositions in β-catenin (CTNNB1) and methods of using them
WO2023009687A1 (en)	2021-07-29	2023-02-02	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
CN117795074A (zh)	2021-08-03	2024-03-29	阿尔尼拉姆医药品有限公司	转甲状腺素蛋白（TTR）iRNA组合物和其使用方法
TW202337474A (zh)	2021-08-04	2023-10-01	美商艾拉倫製藥股份有限公司	用於緘默血管收縮素原（ＡＧＴ）的ｉＲＮＡ組成物及方法
AR126771A1 (es)	2021-08-13	2023-11-15	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ARNi CONTRA EL FACTOR XII (F12) Y SUS MÉTODOS DE USO
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023044370A2 (en)	2021-09-17	2023-03-23	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing complement component 3 (c3)
WO2023044094A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023069603A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023076451A1 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	Complement factor b (cfb) irna compositions and methods of use thereof
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023177866A1 (en)	2022-03-18	2023-09-21	Dicerna Pharmaceuticals, Inc.	Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2024026474A1 (en)	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	Enqp type ii cas proteins and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2002773B (en) *	1977-08-10	1982-03-03	Brown R	Nucleotide inhibitor of protein synthesis
US4210746A (en) *	1978-08-10	1980-07-01	National Research Development Corporation	Nucleotide inhibitor of protein synthesis
US4464359A (en) *	1981-04-10	1984-08-07	Research Corporation	(2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
US4515781A (en) *	1983-02-23	1985-05-07	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	2',5'-Riboadenylate-morpholinoadenylate nucleotides
US4565696A (en) *	1983-08-03	1986-01-21	The Regents Of The University Of California	Production of immunogens by antigen conjugation to liposomes
FR2567892B1 (fr) *	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4663161A (en) *	1985-04-22	1987-05-05	Mannino Raphael J	Liposome methods and compositions
US4781871A (en) *	1986-09-18	1988-11-01	Liposome Technology, Inc.	High-concentration liposome processing method
US4924624A (en) *	1987-10-22	1990-05-15	Temple University-Of The Commonwealth System Of Higher Education	2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5866787A (en) *	1993-03-08	1999-02-02	Cleveland Clinic Foundation	Transgenic plants co-expressing a functional human 2-5A system

1987
- 1987-10-22 US US07/112,591 patent/US4924624A/en not_active Expired - Lifetime
1988
- 1988-10-18 JP JP63509144A patent/JP2733777B2/ja not_active Expired - Fee Related
- 1988-10-18 AT AT95202077T patent/ATE178902T1/de not_active IP Right Cessation
- 1988-10-18 EP EP95202077A patent/EP0694559B1/de not_active Expired - Lifetime
- 1988-10-18 CA CA000580426A patent/CA1339953C/en not_active Expired - Fee Related
- 1988-10-18 AT AT88909900T patent/ATE135579T1/de not_active IP Right Cessation
- 1988-10-18 DE DE3855135T patent/DE3855135T2/de not_active Expired - Fee Related
- 1988-10-18 DE DE3856326T patent/DE3856326T2/de not_active Expired - Fee Related
- 1988-10-18 AU AU26280/88A patent/AU2628088A/en not_active Abandoned
- 1988-10-18 EP EP88909900A patent/EP0389521B1/de not_active Expired - Lifetime
- 1988-10-18 WO PCT/US1988/003634 patent/WO1989003683A1/en active IP Right Grant
1992
- 1992-07-16 US US07/915,771 patent/US5405939A/en not_active Expired - Lifetime
1994
- 1994-12-02 US US08/348,419 patent/US5556840A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATE178902T1 (de)	1999-04-15
EP0389521A1 (de)	1990-10-03
DE3855135D1 (de)	1996-04-25
EP0694559A3 (de)	1996-07-31
DE3855135T2 (de)	1996-09-05
US4924624A (en)	1990-05-15
AU2628088A (en)	1989-05-23
WO1989003683A1 (en)	1989-05-05
JP2733777B2 (ja)	1998-03-30
EP0694559A2 (de)	1996-01-31
US5405939A (en)	1995-04-11
EP0389521A4 (en)	1992-02-05
CA1339953C (en)	1998-07-14
EP0694559B1 (de)	1999-04-14
JPH04500795A (ja)	1992-02-13
US5556840A (en)	1996-09-17
ATE135579T1 (de)	1996-04-15
DE3856326T2 (de)	1999-12-02
EP0389521B1 (de)	1996-03-20

Legal Events

Date	Code	Title	Description
2000-05-11	8364	No opposition during term of opposition
2006-08-17	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE3856326D1 (de)	1999-05-20	2'-5'-Phosphorothioat-Oligoadenylate und deren antivirale Verwendungen
ATE134644T1 (de)	1996-03-15	Weitere antivirale pyrimidin-nukleosiden
DE69330274D1 (de)	2001-07-05	Enantiomerisch reine beta-d-dioxolan-nukleoside
DE68920125D1 (de)	1995-02-02	Pyrimidindion-Derivate, Verfahren zu deren Herstellung und diese enthaltende antiarrythmische Mittel.
FI96947C (fi)	1996-09-25	Menetelmä terapeuttisesti aktiivisten N1-(1,2-cis-2-halogeenisyklopropyyli)substituoitujen pyridonikarboksyylihappojohdannaisten valmistamiseksi
DK232989A (da)	1989-11-14	Antiviralt praeparat
DK108491D0 (da)	1991-06-07	Nucleosider og nucleosidanaloge samt farmaceutiske praeparater indeholdende disse forbindelser
ATE33654T1 (de)	1988-05-15	Antivirale purinderivate.
NO880402L (no)	1988-08-01	Trebehandlingspreparat og behandlingsfremgangsmaate.
DK291390D0 (da)	1990-12-07	Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
ATE90685T1 (de)	1993-07-15	Disaccharidderivate.
NO176609C (no)	1995-05-03	Fremgangsmåte til fremstilling av et sterkt vannlöselig, stabilt, krystallinsk salt av 2',3'-dideoksyinosin, 2',3'-dideoksy-2',3'didehydrotymidin eller 2',3'dideoksy-2'-fluorinosin
FR2571374B1 (fr)	1988-09-09	Nouveaux derives de 5-fluoro-2'-desoxyuridine et leurs sels, leur procede de preparation, et agents antitumoraux les contenant
ES2045146T3 (es)	1994-01-16	Avermectinas etiladas.
FR2577553B1 (fr)	1991-06-21	Derives de l'ergoline et leurs sels formes par addition avec des acides, et leurs applications therapeutiques
FI812773L (fi)	1982-03-13	Foerfarande foer framstaellning av n-/4-/(2,4-diamino-6-pteridinyl)-metyl/metylamino/benzoyl/glutaminsyra
ATE216393T1 (de)	2002-05-15	Salze von glukopyranosederivate und ihre zwischenprodukte
GB8925933D0 (en)	1990-01-04	Glutaric acid derivatives and preparation thereof
ATE101119T1 (de)	1994-02-15	Butensaeure-amide, deren salze, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
KR890003725A (ko)	1989-04-17	아민유도체 및 이의 염, 이의 제조방법 및 이를 함유하는 궤양치료제
TH3422EX (th)	1986-08-01	สารประกอบ
TH3422A (th)	1986-08-01	สารประกอบ